Helomics Launches The DEFENDER Live Cell Liquid Biopsy System

The DEFENDER™ Live Cell Liquid Biopsy System is the world’s only live cell liquid biopsy to detect all components of a patient’s shedding tumor

Novel Proprietary Component of Precision Cellular Analytical Platform (PCAP™), Further Expanding its Comprehensive Tumor Profiling Offering to Patients, Physicians, and Life Science Industry

PITTSBURGH & LONDON--(BUSINESS WIRE)--Helomics® Corporation, a privately-held, personalized healthcare company that provides comprehensive tumor profiling utilizing proprietary live cell and fixed cell products and services, announced today the launch of the DEFENDER™ Live Cell Liquid Biopsy System, a novel proprietary component of precision cellular analytical platform (PCAP™).

The DEFENDER Live Cell Liquid Biopsy System leverages Helomics’ 15 years experience and proprietary science in the ex vivo multi-dimensional culture of human primary or recurrent tumor cells in combination with Helomics’ extensive genomic and proteomic analytical capabilities and expertise. The result is a research and discovery platform that will be used to further enhance Helomics’ tumor biology research and the development of clinical test efforts with collaborators and partner-clients in academia, and in the diagnostics and pharmaceutical industries.

Neil J. Campbell, President & CEO of Helomics, said, “The DEFENDER Live Cell Liquid Biopsy System is an important clinical research and soon to be clinical tool that will lead to a better understanding of the biophysical processes involved in tumor cell shedding, and to the rapid identification and development of new anti-cancer therapies, new treatment markers, and companion diagnostics. We can view and analyze the real-time evolution of tumor metastasis during the proliferation cell cycling of a patient’s tumor. Using our DEFENDER and CellFx platforms, Helomics can investigate fundamental questions of tumor biochemistry, pathology, and gene and protein expression. The combination of these two powerful platforms enables a comprehensive study of the biology of tumors on a highly personalized basis.”

About the DEFENDER™ Live Cell Liquid Biopsy System and CellFx™

The core of both the DEFENDER™ System and CellFx™ platform is Helomics’ ability to grow live human tumors in a proprietary multi-dimensional tissue culture system. Both platforms permit the temporal analysis of cellular shedding, gene expression, and protein expression associated with tumor cell proliferation, tumor cell death, drug response, and/or drug toxicity. Helomics’ proprietary ability to grow human tumors in culture has been meticulously refined for more than 15 years and is currently in its fourth generation of tumor biology elucidation.

About PCAP™

The PCAP™ platform is the basis of Helomics’ comprehensive tumor profiling capability. The platform consists of a suite of technologies for the live and fixed cell analysis of changes in a tumor’s gene regulation, protein expression, and cellular morphology over time or with treatment.

About Helomics® Corporation, Inc.

Helomics® is a comprehensive personalized healthcare company, bringing the next generation of diagnostics to the oncology field. Helomics is dedicated to improving patient outcomes by providing a personalized comprehensive tumor profile utilizing a proprietary set of laboratory platforms that leverage both live and fixed cellular based analysis allowing physicians to characterize malignant tumors on a personalized basis. Helomics’ novel molecular and cellular markers and bioinformatics services support treatment decisions by providing vital information based on the specific biological processes of each individual’s cancer. Helomics is headquartered in Pittsburgh, Pennsylvania where the company maintains two CLIA-certified laboratories. For more information please visit: www.helomics.com.

Forward-Looking Statements

This release may contain forward-looking statements that involve risks and uncertainties. Market conditions and other important factors could cause actual results to differ materially from those communicated in any forward-looking statements, information disclosed in presentations, conference calls or other public venues. We do not intend to update any forward-looking statements after the date of this press release.